PE20170438A1 - Inhibidores espirociclicos de catepsina c - Google Patents

Inhibidores espirociclicos de catepsina c

Info

Publication number
PE20170438A1
PE20170438A1 PE2017000400A PE2017000400A PE20170438A1 PE 20170438 A1 PE20170438 A1 PE 20170438A1 PE 2017000400 A PE2017000400 A PE 2017000400A PE 2017000400 A PE2017000400 A PE 2017000400A PE 20170438 A1 PE20170438 A1 PE 20170438A1
Authority
PE
Peru
Prior art keywords
catepsin
compounds
inhibitors
oxetan
heptan
Prior art date
Application number
PE2017000400A
Other languages
English (en)
Inventor
Viktor Vintonyak
Matthias Grauert
Marc Grundl
Alexander Pautsch
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20170438A1 publication Critical patent/PE20170438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a compuestos de Formula I en donde: A y Cy son como se indica a continuacion. Estos compuestos son inhibidores de catepsina C y estan relacionados con el tratamiento de enfermedades relacionadas con la actividad de dipeptidil peptidasa I, por ejemplo, enfermedades respiratorias. Entre los compuestos preferidos tenemos los siguientes: (1S,2S,4R)-N-[(1S)-1-ciano-2-[2-fluoro-4-[1'-(oxetan-3-il)spiro[1H-isobenzofuran-3,4'piperidin]-5-il]fenil]etil]-3-azabiciclo[2.2.1]heptan-2-carboxamida; (1S,2S,4R)-N-[(1S)-1-ciano-2-[2-fluoro-4-[1'-(oxetan-3-il)spiro[3H-furo[3,4-c]piridin-1,4'piperidin]-6-il]fenil]etil]-3-azabiciclo[2.2.1]heptan-2-carboxamida; entre otros
PE2017000400A 2014-09-12 2015-09-08 Inhibidores espirociclicos de catepsina c PE20170438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12

Publications (1)

Publication Number Publication Date
PE20170438A1 true PE20170438A1 (es) 2017-04-28

Family

ID=51535355

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000400A PE20170438A1 (es) 2014-09-12 2015-09-08 Inhibidores espirociclicos de catepsina c

Country Status (34)

Country Link
US (3) US9540373B2 (es)
EP (2) EP3511331A1 (es)
JP (2) JP2017526716A (es)
KR (1) KR102510588B1 (es)
CN (2) CN107074870B (es)
AP (1) AP2017009733A0 (es)
AU (1) AU2015314355B2 (es)
BR (1) BR112017003433B1 (es)
CA (1) CA2960916C (es)
CL (1) CL2017000432A1 (es)
CO (1) CO2017002268A2 (es)
CY (1) CY1123033T1 (es)
DK (1) DK3191487T3 (es)
EA (1) EA031376B1 (es)
ES (1) ES2749009T3 (es)
HK (1) HK1255362A1 (es)
HR (1) HRP20191756T1 (es)
HU (1) HUE047208T2 (es)
IL (1) IL250262B (es)
LT (1) LT3191487T (es)
MX (2) MX367316B (es)
MY (1) MY188382A (es)
NZ (1) NZ728684A (es)
PE (1) PE20170438A1 (es)
PH (1) PH12017500453A1 (es)
PL (1) PL3191487T3 (es)
PT (1) PT3191487T (es)
RS (1) RS59444B1 (es)
SA (1) SA517381064B1 (es)
SG (1) SG11201701633SA (es)
SI (1) SI3191487T1 (es)
TW (1) TWI687424B (es)
UA (1) UA118610C2 (es)
WO (1) WO2016038007A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018227B2 (en) 2010-03-19 2015-04-28 Indiana State University Nicotinic acetylcholine receptor agonists
NO2699580T3 (es) 2014-01-24 2018-02-24
JP6529575B2 (ja) * 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
UA118610C2 (uk) * 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
JP2021512904A (ja) * 2018-02-07 2021-05-20 インスメッド インコーポレイテッド Ａｎｃａ関連血管炎の治療のためのある種の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニル］−１，４−オキサゼパン−２−カルボキサミド
MA52424A (fr) 2018-03-01 2021-01-06 Astrazeneca Ab Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
CN114106005A (zh) * 2020-08-26 2022-03-01 四川海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
JP7563101B2 (ja) 2020-10-14 2024-10-08 東亞合成株式会社 剥離性接着物製造用硬化性組成物、剥離性接着物、並びに、剥離方法
JP7563100B2 (ja) 2020-10-14 2024-10-08 東亞合成株式会社 仮固定用硬化性組成物、及び、仮固定方法
CA3199568A1 (en) * 2020-12-04 2022-06-09 Reistone Biopharma Company Limited Small molecule inhibitor of cathepsin c and medicinal use thereof
WO2023243601A1 (ja) * 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
AU2002254099B2 (en) 2001-03-02 2006-07-06 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
JP2006527704A (ja) 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
WO2006096807A1 (en) 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
WO2007137738A1 (de) * 2006-06-01 2007-12-06 Sanofi-Aventis Spiro-cyclische nitrile als protease-inhibitoren
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
WO2009047829A1 (ja) 2007-10-12 2009-04-16 Fujitsu Limited Ｉｐ電話自動試験システム及び方法
MX2010006110A (es) 2007-12-12 2010-06-25 Astrazeneca Ab Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i.
SG175090A1 (en) 2009-05-07 2011-11-28 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
US9428452B2 (en) 2012-04-27 2016-08-30 Glaxo Group Limited Compounds
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
MX2015004016A (es) 2012-09-28 2016-02-18 Ignyta Inc Inhibidores de azaquinazolina de la proteina quinasa c atipica.
EP2908806A1 (en) * 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
BR112015008487B1 (pt) 2012-10-15 2022-05-31 Epizyme, Inc Compostos de benzeno substituído, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos para tratar um distúrbio mediado por ezh2
CA2888210C (en) 2012-10-16 2021-02-09 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
MX2015005428A (es) 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
SG11201504946VA (en) 2012-12-21 2015-07-30 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
WO2014100620A2 (en) 2012-12-21 2014-06-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
MA38493B1 (fr) 2013-03-14 2017-10-31 Newlink Genetics Corp Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane
AP2015008601A0 (en) 2013-03-14 2015-07-31 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014140091A1 (en) * 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
DK3137136T3 (en) * 2014-04-29 2018-07-23 Carebay Europe Ltd DEVICE FOR ADJUSTING DEADLINE DEPTH
US20160001608A1 (en) 2014-07-03 2016-01-07 Bridgestone Americas Tire Operations, Llc Sidewall decoration on rim guard
UA118610C2 (uk) * 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
TW201625591A (zh) 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
SG11201701043UA (en) 2014-09-12 2017-03-30 Glaxosmithkline Ip No 2 Ltd Tetrahydroquinoline derivatives as bromodomain inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Also Published As

Publication number Publication date
HRP20191756T1 (hr) 2019-12-27
EP3511331A1 (en) 2019-07-17
LT3191487T (lt) 2019-10-10
EA031376B1 (ru) 2018-12-28
BR112017003433B1 (pt) 2023-11-14
TWI687424B (zh) 2020-03-11
CN107074870A (zh) 2017-08-18
AU2015314355A1 (en) 2017-02-16
IL250262B (en) 2020-03-31
US20170073352A1 (en) 2017-03-16
DK3191487T3 (da) 2019-10-28
JP2018044011A (ja) 2018-03-22
RS59444B1 (sr) 2019-11-29
USRE47636E1 (en) 2019-10-08
HUE047208T2 (hu) 2020-04-28
MX2019009695A (es) 2019-10-07
TW201625647A (zh) 2016-07-16
WO2016038007A1 (en) 2016-03-17
KR102510588B1 (ko) 2023-03-17
MY188382A (en) 2021-12-07
CO2017002268A2 (es) 2017-06-20
CN108047240B (zh) 2020-08-04
PL3191487T3 (pl) 2020-03-31
US20160075704A1 (en) 2016-03-17
EA201790576A1 (ru) 2017-08-31
US9540373B2 (en) 2017-01-10
MX367316B (es) 2019-08-15
CL2017000432A1 (es) 2017-10-20
AU2015314355B2 (en) 2019-06-20
ES2749009T3 (es) 2020-03-18
SI3191487T1 (sl) 2019-12-31
IL250262A0 (en) 2017-03-30
PT3191487T (pt) 2019-11-18
CN107074870B (zh) 2019-07-12
BR112017003433A2 (pt) 2017-11-28
UA118610C2 (uk) 2019-02-11
JP6360961B2 (ja) 2018-07-18
PH12017500453B1 (en) 2017-07-31
NZ728684A (en) 2022-09-30
CA2960916A1 (en) 2016-03-17
US9879026B2 (en) 2018-01-30
SG11201701633SA (en) 2017-03-30
HK1255362A1 (zh) 2019-08-16
SA517381064B1 (ar) 2021-02-07
KR20170054489A (ko) 2017-05-17
EP3191487A1 (en) 2017-07-19
CY1123033T1 (el) 2021-10-29
EP3191487B1 (en) 2019-08-07
CN108047240A (zh) 2018-05-18
AP2017009733A0 (en) 2017-02-28
PH12017500453A1 (en) 2017-07-31
CA2960916C (en) 2023-03-07
MX2017003156A (es) 2017-05-23
JP2017526716A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
PE20170438A1 (es) Inhibidores espirociclicos de catepsina c
CO7310529A2 (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano rory
CL2018000292A1 (es) Compuestos farmacéuticos
PH12014502570A1 (en) Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
PE20161251A1 (es) Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4
PE20151605A1 (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos de los mismos como inhibidores de autotaxina
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
EA202190619A1 (ru) Противовирусные соединения
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
CR20150057A (es) Antagonistas del receptor de 5-ht3
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
PE20151892A1 (es) Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas
PH12018500378A1 (en) Novel annelated phenoxyacetamides
UY35338A (es) Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
PE20170427A1 (es) Peptidos como agonistas de la oxitocina
DK2257526T3 (da) Spiro(5,5)undecan-derivater
TN2011000223A1 (en) Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
EA201491251A1 (ru) Соединение 2-(пиридин-2-ил)-1,7-диазаспиро[4.4]нонан-6-она в качестве модуляторов потенциалзависимых натриевых каналов
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
EA201591023A1 (ru) Твердая форма производного дигидропиридооксазина
ECSP15007708A (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano ror[gamma]